

Marco Valgimigli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4480299/publications.pdf>

Version: 2024-02-01

667
papers

92,677
citations

1371

108
h-index

322

288
g-index

732
all docs

732
docs citations

732
times ranked

45029
citing authors

#	ARTICLE	IF	CITATIONS
1	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 216-226.	3.0	23
2	PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 28-38.	3.0	39
3	Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum. <i>European Heart Journal</i> , 2022, 43, 940-958.	2.2	8
4	Five-Year Outcomes With Biodegradable-Polymer Sirolimus-Eluting Stents Versus Durable-Polymer Everolimus-Eluting Stents in Patients With Acute Coronary Syndrome: A Subgroup Analysis of the BIOSCIENCE Trial. <i>Cardiovascular Revascularization Medicine</i> , 2022, 34, 3-10.	0.8	5
5	Bleeding avoidance strategies in percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 117-132.	13.7	71
6	Clinical impact of left atrial appendage filling defects in patients undergoing transcatheter aortic valve implantation. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1354-1364.	1.2	2
7	Management of acute coronary syndromes in older adults. <i>European Heart Journal</i> , 2022, 43, 1542-1553.	2.2	24
8	Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 492-502.	3.0	22
9	Atrial Interventions. , 2022, , 309-337.		0
10	â€œTailoredâ€•antiplatelet bridging therapy with cangrelor: moving toward personalized medicine. <i>Platelets</i> , 2022, 33, 687-691.	2.3	6
11	Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial. <i>Circulation</i> , 2022, 145, 724-738.	1.6	61
12	Distal Transradial Access for Coronary Procedures. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 33-38.	2.9	2
13	The Effects of Cangrelor on Platelet Aggregation in STEMI Patients. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 229-230.	2.9	0
14	Patients With Atrial Fibrillation and PCI or ACS. <i>Journal of the American College of Cardiology</i> , 2022, 79, 428-431.	2.8	1
15	Watchman FLX vs. Watchman 2.5 in a Dual-Center Left Atrial Appendage Closure Cohort: the WATCH-DUAL study. <i>Europace</i> , 2022, 24, 1441-1450.	1.7	18
16	Self-reported non-adherence to P2Y12 inhibitors in patients undergoing percutaneous coronary intervention: Application of the medication non-adherence academic research consortium classification. <i>PLoS ONE</i> , 2022, 17, e0263180.	2.5	3
17	Not only lungs: COVID-19 hits platelets as well. <i>European Heart Journal</i> , 2022, 43, 2092-2093.	2.2	2
18	Sex Differences in Outcomes After Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Left Main Disease: From the DELTA Registries. <i>Journal of the American Heart Association</i> , 2022, 11, e022320.	3.7	5

#	ARTICLE	IF	CITATIONS
19	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Per-Protocol Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024291.	3.7	4
20	Left ventricular thrombus in ischaemic heart disease: diagnosis, treatment, and gaps of knowledge. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 496-509.	4.0	4
21	A prospective, first-in-human use of the NeVa mechanical thrombectomy device for patients with acute coronary syndromes. <i>EuroIntervention</i> , 2022, 18, 242-252.	3.2	6
22	Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	2.1	0
23	Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 100, 72-82.	1.7	4
24	Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. <i>European Heart Journal</i> , 2022, 43, 3100-3114.	2.2	38
25	Radial vs Femoral Access in ACS Patients Undergoing Complex PCI Is Associated With Consistent Bleeding Benefit and No Excess of Risks. <i>Canadian Journal of Cardiology</i> , 2022, 38, 1488-1500.	1.7	3
26	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. <i>Nature Reviews Cardiology</i> , 2022, 19, 829-844.	13.7	30
27	Comparative Outcomes After Percutaneous Coronary Intervention in Unconscious and Conscious Patients With Out-of-Hospital Cardiac Arrest. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 1338-1348.	2.9	4
28	Clinical and echocardiographic risk factors for device-related thrombus after left atrial appendage closure: an analysis from the multicenter EURO-C-DRT registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 1276-1285.	3.3	10
29	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimus-eluting stents. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1111-1119.	1.7	2
30	Antithrombotic therapy in heart failure and sinus rhythm: the ongoing search for a better match of patients to therapy. <i>European Journal of Heart Failure</i> , 2021, 23, 657-660.	7.1	0
31	Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 352-359.	3.0	8
32	Profile and treatment of chronic coronary syndromes in European Society of Cardiology member countries: The ESC EORP CICD-LT registry. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 432-445.	1.8	11
33	Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 68-73.	3.0	9
34	Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over Prasugrel: a Multicenter Randomized Open-label Trial in Patients with ST-elevation Myocardial Infarction Referred for Primary Percutaneous Intervention (FABOLUS FASTER) Trial: Design and Rationale. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 110-119.	2.4	7
35	Impact of individual stroke risk on outcome after Amplatzer left atrial appendage closure in patients with atrial fibrillation. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E1002-E1010.	1.7	2
36	Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. <i>American Heart Journal</i> , 2021, 231, 147-156.	2.7	21

#	ARTICLE	IF	CITATIONS
37	Usefulness of updated logistic clinical SYNTAX score based on MIâ€SYNTAX score in patients with STâ€elevation myocardial infarction. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E919-E928.	1.7	4
38	Impact of optical coherence tomography findings on clinical outcomes in ST-segment elevation myocardial infarction patients: a MATRIX (Minimizing Adverse Hemorrhagic Events by Trans-radial) Tj ETQq0 0 0 rgBT _{1,5} /Overlock 10 Tf 50 1143-1150.	1.5	1
39	Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2021, 42, 308-319.	2.2	90
40	Discharge Location and Outcomes After Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 140, 95-102.	1.6	2
41	Bleeding risk prediction in elderly patients managed invasively for acute coronary syndromes: External validation of the PRECISE-DAPT and PARIS scores. <i>International Journal of Cardiology</i> , 2021, 328, 22-28.	1.7	14
42	Regional variation in patients and outcomes in the GLOBAL LEADERS trial. <i>International Journal of Cardiology</i> , 2021, 324, 30-37.	1.7	4
43	Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f50-f60.	3.0	24
44	Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A) Tj ETQq0 0 0 rgBT _{1,5} /Overlock 10 Tf 50 4	1.5	1
45	Clinical risk predictors in atrial fibrillation patients following successful coronary stenting: ENTRUST-AF PCI sub-analysis. <i>Clinical Research in Cardiology</i> , 2021, 110, 831-840.	3.3	14
46	2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2021, 42, 1289-1367.	2.2	3,048
47	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	2.2	5,583
48	The ESC-EORP Chronic Ischaemic Cardiovascular Disease Long Term (CICD LT) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 28-33.	4.0	2
49	Composition, structure, and function of heart teams: a joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 83-93.	1.0	4
50	Patient-tailored antithrombotic therapy following percutaneous coronary intervention. <i>European Heart Journal</i> , 2021, 42, 1038-1046.	2.2	28
51	Competing risks in the duration of dual antiplatelet therapyâ€”the case for shorter treatment. , 2021, , 111-130.		0
52	Composition, structure, and function of heart teams: a joint position paper of the ACVC, EAPCI, EACTS, and EACTA focused on the management of patients with complex coronary artery disease requiring myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2021, 59, 522-531.	1.4	3
53	European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. <i>European Heart Journal</i> , 2021, 42, 1545-1553.	2.2	32
54	Ischaemic and bleeding risk in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: is it time to REACT?. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1125-1128.	1.0	8

#	ARTICLE	IF	CITATIONS
55	Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 444-456.	2.9	27
56	Predicting 2-year all-cause mortality after contemporary <sc>PCI</sc>: Updating the logistic clinical <sc>SYNTAX</sc> score. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1287-1297.	1.7	6
57	Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2021, 77, 375-388.	2.8	70
58	Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006581.	2.2	10
59	Cardiovascular mortality and morbidity in patients undergoing percutaneous coronary intervention after out-of-hospital cardiac arrest: a systematic review and meta-analysis. <i>EuroIntervention</i> , 2021, 16, e1245-e1253.	3.2	5
60	Access-Site Crossover in Patients With Acute Coronary Syndrome Undergoing Invasive Management. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 361-373.	2.9	25
61	Single antiplatelet therapy with use of prasugrel in patients undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E213-E221.	1.7	3
62	Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 419-428.	2.1	2
63	Biodegradable- Versus Durable-Polymer Drug-Eluting Stents for STEMI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 639-648.	2.9	33
64	Response by Gargiulo et al to Letter Regarding Article, "Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment Elevation Myocardial Infarction: Primary Results of the FABOLUS FASTER Trial". <i>Circulation</i> , 2021, 143, e797-e798.	1.6	0
65	Sex differences in distribution, management and outcomes of combined ischemic-bleeding risk following acute coronary syndrome. <i>International Journal of Cardiology</i> , 2021, 329, 16-22.	1.7	8
66	Assessing the Risks of Bleeding vs Thrombotic Events in Patients at High Bleeding Risk After Coronary Stent Implantation. <i>JAMA Cardiology</i> , 2021, 6, 410.	6.1	52
67	Design and Rationale of the Swiss-Apero Randomized Clinical Trial: Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure. <i>Journal of Cardiovascular Translational Research</i> , 2021, 14, 930-940.	2.4	7
68	From secondary to tertiary mitral regurgitation: the paradigm shifts, but uncertainties remain. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 835-843.	1.2	6
69	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2021, 42, 4638-4651.	2.2	80
70	External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E513-E522.	1.7	1
71	Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions. <i>EuroIntervention</i> , 2021, 17, 59-66.	3.2	21
72	Device-Related Thrombus After Left Atrial Appendage Closure: Data on Thrombus Characteristics, Treatment Strategies, and Clinical Outcomes From the EUROCC-DRT-Registry. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010195.	3.9	46

#	ARTICLE	IF	CITATIONS
73	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2021, 373, n1332.	6.0	144
74	Large-Bore Radial Access for Complex PCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1304-1307.	2.9	4
75	Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTEMI-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. <i>European Heart Journal</i> , 2021, 42, 2973-2985.	2.2	21
76	Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. <i>Journal of the American Heart Association</i> , 2021, 10, e021965.	3.7	23
77	Multivessel percutaneous coronary intervention with thin-strut biodegradable versus durable polymer drug-eluting stents in ST-segment elevation myocardial infarction: A subgroup analysis of the BIOSTEMI randomized trial. <i>International Journal of Cardiology</i> , 2021, 334, 37-41.	1.7	2
78	Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. <i>New England Journal of Medicine</i> , 2021, 385, 2150-2160.	27.0	144
79	Impact of Echocardiographic Guidance on Safety and Efficacy of Left Atrial Appendage Closure. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1815-1826.	2.9	13
80	Subcutaneous RUC-4 for acute myocardial infarction: a new treatment on the horizon for pre-hospital care?. <i>EuroIntervention</i> , 2021, 17, e362-e363.	3.2	1
81	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021, 78, 421-433.	2.8	58
82	Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2021, 385, 1643-1655.	27.0	247
83	Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous intervention. <i>International Journal of Cardiology</i> , 2021, 337, 1-8.	1.7	6
84	Intimal Flap Sealing and Healing of Spontaneous Coronary Artery Dissection With Drug-Eluting Balloons. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1843-1845.	2.9	0
85	Comparative frequency and prognostic impact of myocardial injury in hospitalized patients with COVID-19 and Influenza. <i>European Heart Journal Open</i> , 2021, 1, .	2.3	11
86	Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial. <i>Circulation</i> , 2021, 144, 1196-1211.	1.6	41
87	Selatogrel and other P2Y12 inhibitors' putative off-target effects. <i>Journal of Cardiovascular Pharmacology</i> , 2021, Publish Ahead of Print, .	1.9	0
88	Ticagrelor versus prasugrel in acute coronary syndrome: sex-specific analysis from the RENAMI Registry. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 408-416.	0.7	3
89	Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis. <i>EuroIntervention</i> , 2021, 17, 550-560.	3.2	31
90	Acute kidney injury in patients with acute coronary syndrome undergoing invasive management treated with bivalirudin vs. unfractionated heparin: insights from the MATRIX trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1170-1179.	1.0	4

#	ARTICLE	IF	CITATIONS
91	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1870-1883.	2.9	56
92	Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre-specified Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e015560.	3.7	18
93	Comparing methods for estimating patient-specific treatment effects in individual patient data meta-analysis. <i>Statistics in Medicine</i> , 2021, 40, 1553-1573.	1.6	19
94	Impact of clinical presentation on bleeding risk after percutaneous coronary intervention and implications for the ARC-HBR definition. <i>EuroIntervention</i> , 2021, 17, e898-e909.	3.2	45
95	A new iteration for the single-access large-bore technique during Impella supported complex and high-risk coronary intervention: a case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab428.	0.6	3
96	Drug-Eluting or Bare-Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization. <i>Journal of the American Heart Association</i> , 2021, 10, e018828.	3.7	4
97	Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021, 144, 1323-1343.	1.6	35
98	Validation and Additive Predictive Value of the Academic Research Consortium's High Bleeding Risk Criteria in Older Adults. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1255-1257.	3.4	4
99	The multiplication of loaves and fishes approach: a critic to double anti-thrombotics or to double number of ischaemic events?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e29-e30.	3.0	0
100	Risk-Benefit of 1-Year DAPT After DES Implantation in Patients Stratified by Bleeding and Ischemic Risk. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1968-1986.	2.8	11
101	Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2060-2072.	2.8	39
102	Prediction of radial crossover in acute coronary syndromes: derivation and validation of the MATRIX score. <i>EuroIntervention</i> , 2021, 17, e971-e980.	3.2	13
103	Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. <i>Europace</i> , 2020, 22, 33-46.	1.7	54
104	Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 100-111.	1.7	16
105	Does isolated mitral annular calcification in the absence of mitral valve disease affect clinical outcomes after transcatheter aortic valve replacement?. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 522-532.	1.2	28
106	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 407-477.	2.2	4,210
107	Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 203-210.	3.0	69
108	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 120-129.	27.0	362

#	ARTICLE	IF	CITATIONS
109	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 21.	6.1	49
110	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. <i>Canadian Journal of Cardiology</i> , 2020, 36, 747-755.	1.7	2
111	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. <i>Circulation</i> , 2020, 141, 781-783.	1.6	80
112	Assessment of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing bivalirudin versus unfractionated heparin infusion: The MATRIX (minimizing adverse) Tj ETQq0 0 0 rgBT/Overlock_10 Tf 50 6 Cardiovascular Interventions, 2020, 96, 1156-1171.	1.7	2
113	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 222-230.	3.0	7
114	Intolerance to aspirin in patients undergoing percutaneous coronary intervention in the setting of chronic coronary syndromes: perspectives from the ESC 2019 Chronic Coronary Syndromes guidelines. <i>European Heart Journal</i> , 2020, 41, 483-484.	2.2	2
115	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1369-1378.	1.7	6
116	A Critical Comparison of Canadian and International Guidelines Recommendations for Antiplatelet Therapy in Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1298-1307.	1.7	12
117	Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and Methodology. <i>Thrombosis and Haemostasis</i> , 2020, 120, 348-362.	3.4	13
118	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 918-929.	3.3	3
119	Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. <i>International Journal of Cardiology</i> , 2020, 301, 200-206.	1.7	26
120	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 22-30.	3.0	7
121	The benefit and harm of treating STEMI: Between ischemia, bleeding, and reperfusion injury. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 259-261.	1.0	0
122	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 179.	6.8	14
123	Ultrathin-Strut Versus Thin-Strut Drug-Eluting Stents for Primary PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2314-2316.	2.9	0
124	Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. <i>European Heart Journal</i> , 2020, 41, 3743-3749.	2.2	89
125	Long-Term Risk of Major Adverse Cardiovascular Events in Patients With Acute Coronary Syndrome: Prognostic Role of Complete Blood Cell Count. <i>Angiology</i> , 2020, 71, 831-839.	1.8	0
126	Lugar de acceso y tipo de anticoagulante en pacientes con síndrome coronario agudo en clase Killip avanzada o con parada cardiaca extrahospitalaria. <i>Revista Espanola De Cardiologia</i> , 2020, 73, 893-901.	1.2	5

#	ARTICLE	IF	CITATIONS
127	Long-Term Prognostic Impact of Restenosis of the Unprotected Left Main Coronary Artery Requiring Repeat Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2266-2274.	2.9	13
128	Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. <i>International Journal of Cardiology</i> , 2020, 320, 27-34.	1.7	4
129	A 4-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making. <i>American Heart Journal</i> , 2020, 223, 44-47.	2.7	17
130	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006660.	2.2	11
131	Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. <i>European Heart Journal</i> , 2020, 41, 4497-4504.	2.2	20
132	Impact of Bleeding and Myocardial Infarction on Mortality in All-Comer Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009177.	3.9	15
133	Long-Term Bleeding Risk Prediction with Dual Antiplatelet Therapy After Acute Coronary Syndromes Treated Without Revascularization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006582.	2.2	5
134	Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1468-1483.	2.8	35
135	Effects of Fentanyl Versus Morphine on Ticagrelor-Induced Platelet Inhibition in Patients With ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2020, 142, 2479-2481.	1.6	9
136	Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2982-3021.	2.8	4,468
137	No free lunch—the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI. <i>Annals of Translational Medicine</i> , 2020, 8, 516-516.	1.7	0
138	Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1067-1077.	4.7	32
139	Platelet Inhibition, Endothelial Function, and Clinical Outcome in Patients Presenting With ST-Segment Elevation Myocardial Infarction Randomized to Ticagrelor Versus Prasugrel Maintenance Therapy: Long-Term Follow-Up of the REDUCE-MVI Trial. <i>Journal of the American Heart Association</i> , 2020, 9, e014411.	3.7	15
140	Antithrombotic treatment strategies after PCI – Authors' reply. <i>Lancet, The</i> , 2020, 395, 867-868.	13.7	0
141	Choice of access site and type of anticoagulant in acute coronary syndromes with advanced Killip class or out-of-hospital cardiac arrest. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020, 73, 893-901.	0.6	7
142	Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment Elevation Myocardial Infarction. <i>Circulation</i> , 2020, 142, 441-454.	1.6	67
143	Higher risk of stent thrombosis with double therapy with direct oral anticoagulants: cherry picking the populations of interest does not help. <i>European Heart Journal</i> , 2020, 41, 1701-1702.	2.2	3
144	DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 634-646.	2.9	17

#	ARTICLE	IF	CITATIONS
145	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. <i>Atherosclerosis</i> , 2020, 295, 45-53.	0.8	36
146	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. <i>Circulation</i> , 2020, 141, 891-901.	1.6	28
147	Clinical outcomes of Watchman vs. Amplatzer occluders for left atrial appendage closure (WATCH at) Tj ETQq1 1 0,784314 rgBT /Ove	1.7	18
148	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 930-943.	3.3	14
149	Device profile of the XIENCE V and XIENCE Sierra stents for the treatment of coronary artery disease: an overview of safety and efficacy. <i>Expert Review of Medical Devices</i> , 2020, 17, 383-390.	2.8	6
150	Sex-Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patient-Level Pooled Analysis From 4 Postapproval Studies. <i>Journal of the American Heart Association</i> , 2020, 9, e014611.	3.7	12
151	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E516-E526.	1.7	5
152	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1125-1139.	3.3	14
153	Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2588-2597.	2.8	53
154	Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2020, 16, 634-644.	3.2	6
155	The SYNTAX score on its way out or â€¦ towards artificial intelligence: part I. <i>EuroIntervention</i> , 2020, 16, 44-59.	3.2	26
156	The SYNTAX score on its way out or â€¦ towards artificial intelligence: part II. <i>EuroIntervention</i> , 2020, 16, 60-75.	3.2	18
157	Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2020, 15, e1605-e1614.	3.2	20
158	Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. <i>EuroIntervention</i> , 2020, 16, 371-379.	3.2	132
159	Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. <i>EuroIntervention</i> , 2020, 16, 627-633.	3.2	18
160	The impact of the COVID-19 pandemic upon patients, staff, and on the future practices of percutaneous coronary intervention. <i>European Heart Journal Supplements</i> , 2020, 22, P13-P18.	0.1	4
161	Therapeutic Considerations with Revascularization in Chronic Kidney Disease: Radial Versus Femoral Arterial Access. , 2020, , 85-101.		0
162	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	2.2	2,687

#	ARTICLE	IF	CITATIONS
163	2019 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (EAACC). <i>Journal of the American College of Cardiology</i> , 2019, 73, 1172-1193.	1.7	209
164	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). <i>European Heart Journal</i> , 2019, 40, 2070-2085.	2.2	64
165	Impact of Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007734.	3.9	6
166	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. <i>European Heart Journal</i> , 2019, 40, 2595-2604.	2.2	93
167	Everolimus-Eluting Biodegradable Polymer Versus Everolimus-Eluting Durable Polymer Stent for Coronary Revascularization in Routine Clinical Practice. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1665-1675.	2.9	23
168	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 74, 162-163.	2.8	1
169	PREDICTIVE ABILITY OF THE PARIS RISK SCORE IN ALL-COMERS PATIENTS UNDERGOING PCI WITH DRUG ELUTING STENTS: EXTERNAL VALIDATION IN THE GLOBAL LEADERS STUDY. <i>Journal of the American College of Cardiology</i> , 2019, 73, 245.	2.8	1
170	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 618-628.	11.4	207
171	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537.	2.9	366
172	Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. <i>European Heart Journal</i> , 2019, 40, 3757-3767.	2.2	211
173	Five-Year Outcomes in Patients With Diabetes Mellitus Treated With Biodegradable Polymer Sirolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents. <i>Journal of the American Heart Association</i> , 2019, 8, e013607.	3.7	17
174	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2223-2234.	2.8	101
175	Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2015-2027.	2.8	23
176	Femoral Access With or Without Vascular Closure Device or Radial Access in Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2116-2118.	2.9	6
177	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). <i>American Journal of Cardiology</i> , 2019, 124, 1833-1840.	1.6	5
178	Prognostic Relevance of Left Ventricular Myocardial Performance After Transcatheter Aortic Valve Replacement. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e006612.	3.9	4
179	The Use of Radial Access for Cardiac Catheterization. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2257-2259.	2.9	1
180	ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. <i>Journal of Electrocardiology</i> , 2019, 57, 44-54.	0.9	7

#	ARTICLE	IF	CITATIONS
181	Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention?. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007705.	3.9	6
182	Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. <i>Lancet, The</i> , 2019, 394, 1243-1253.	13.7	138
183	Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. <i>Lancet, The</i> , 2019, 394, 1335-1343.	13.7	465
184	Ticagrelor in patients with diabetes and previous PCI. <i>Lancet, The</i> , 2019, 394, 1118-1120.	13.7	1
185	Prosthesis-Patient Mismatch Following Transcatheter Aortic Valve Replacement With Supra-Annular and Intra-Annular Prostheses. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2173-2182.	2.9	60
186	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 1092.	6.1	97
187	OCT Appraisal of Residual Thrombus Burden in Patients With STEMI Undergoing Intraprocedural Versus Post-Stenting Prolonged Bivalirudin Infusion. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 934-936.	5.3	3
188	Association of acute kidney injury and bleeding events with mortality after radial or femoral access in patients with acute coronary syndrome undergoing invasive management: secondary analysis of a randomized clinical trial. <i>European Heart Journal</i> , 2019, 40, 1226-1232.	2.2	26
189	Obstructive sleep apnoea syndrome and endothelial function: potential impact of different treatment strategies" meta-analysis of prospective studies. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 2331-2338.	1.6	3
190	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	2.2	335
191	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.	1.6	428
192	The MATRIX trial " Author's reply. <i>Lancet, The</i> , 2019, 393, 1803-1804.	13.7	0
193	Use of PRECISE-DAPT Score and Admission Platelet Count to Predict Mortality Risk in Patients With Acute Coronary Syndrome. <i>Angiology</i> , 2019, 70, 867-877.	1.8	10
194	Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 810-822.	4.5	18
195	Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 820-830.	2.9	36
196	Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. <i>Lancet, The</i> , 2019, 393, 2503-2510.	13.7	166
197	Impact of left ventricular function on clinical outcomes among patients with coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1273-1284.	1.8	16
198	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-Study (GLASSY). <i>BMJ Open</i> , 2019, 9, e026053.	1.9	18

#	ARTICLE	IF	CITATIONS
199	Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007541.	3.9	19
200	Comparison of intra-procedural vs. post-stenting prolonged bivalirudin infusion for residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing: the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and angioX) OCT study. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1418-1428.	1.2	5
201	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. <i>International Journal of Cardiology</i> , 2019, 286, 43-50.	1.7	19
202	Mechanical complications in patients with ST-segment elevation myocardial infarction: A single centre experience. <i>PLoS ONE</i> , 2019, 14, e0209502.	2.5	21
203	Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 73, 741-754.	2.8	218
204	Post-Procedural Bivalirudin Infusion at Full or Low Regimen in Patients With Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2019, 73, 758-774.	2.8	22
205	Complete revascularisation in STEMI: consider the benefits but do not forget the risks!. <i>Annals of Translational Medicine</i> , 2019, 7, S331-S331.	1.7	0
206	Best Practices for the Prevention of Radial Artery Occlusion After Transradial Diagnostic Angiography and Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2235-2246.	2.9	111
207	Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: CardioOncology</i> , 2019, 1, 145-155.	4.0	20
208	Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 158-163.	3.0	11
209	The remarkable story of a wonder drug, which now comes to an end in the primary prevention setting: say bye-bye to aspirin!. <i>European Heart Journal</i> , 2019, 40, 618-620.	2.2	10
210	Racial Differences in Ischaemia/Bleeding Risk Trade-Off during Anti-Platelet Therapy: Individual Patient Level Landmark Meta-Analysis from Seven RCTs. <i>Thrombosis and Haemostasis</i> , 2019, 119, 149-162.	3.4	107
211	Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. <i>American Heart Journal</i> , 2019, 209, 97-105.	2.7	53
212	Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention?. <i>European Heart Journal</i> , 2019, 40, 216-217.	2.2	32
213	Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine. <i>American Journal of Cardiovascular Drugs</i> , 2019, 19, 173-183.	2.2	23
214	European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. <i>European Heart Journal</i> , 2019, 40, 3182-3195.	2.2	240
215	Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel. <i>Circulation</i> , 2019, 139, 636-646.	1.6	40
216	Application of the MADS classification system in a "omega mammoth" stent trial: Feasibility and preliminary clinical implications. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 57-63.	1.7	5

#	ARTICLE	IF	CITATIONS
217	Impact of angiographic coronary artery disease complexity on ischemic and bleeding risks and on the comparative effectiveness of zotarolimus-eluting vs. bare-metal stents in uncertain drug-eluting stent candidates. <i>International Journal of Cardiology</i> , 2019, 277, 60-65.	1.7	2
218	Prognostic Value of Right Ventricular Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 577-587.	5.3	85
219	A call for action in bleeding prevention. <i>Aging</i> , 2019, 11, 287-288.	3.1	3
220	Impact of sex on comparative outcomes of bivalirudin versus unfractionated heparin in patients with acute coronary syndromes undergoing invasive management: a pre-specified analysis of the MATRIX trial. <i>EuroIntervention</i> , 2019, 15, e269-e278.	3.2	2
221	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e539-e546.	3.2	16
222	Computed tomography detection and quantification of left atrial appendage residual patency as collateral finding after percutaneous closure. <i>International Journal of Cardiology</i> , 2018, 260, 42-46.	1.7	11
223	Operators' experience with radial access for cardiac catheterization in patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2018, 257, 35.	1.7	1
224	The Radial Artery for Percutaneous Coronary Procedures or Surgery?. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1167-1175.	2.8	26
225	A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 417-434.	2.9	81
226	The Impact of Left Ventricular Diastolic Dysfunction on Clinical Outcomes After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 593-601.	2.9	58
227	Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 852-863.	3.4	0
228	Quantitative Flow Ratio Identifies Nonculprit Coronary Lesions Requiring Revascularization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006023.	3.9	80
229	Early versus newer generation devices for transcatheter aortic valve implantation in routine clinical practice: a propensity score matched analysis. <i>Open Heart</i> , 2018, 5, e000695.	2.3	36
230	Short-Term Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Elderly Patients. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 435-443.	2.9	54
231	“Ten Commandments” of the 2017 ESC DAPT focused update Guidelines. <i>European Heart Journal</i> , 2018, 39, 186-186.	2.2	0
232	The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up. <i>European Journal of Preventive Cardiology</i> , 2018, 25, 377-387.	1.8	12
233	Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION) <i>Tj ETQq1 1 0.784314 rgBT /Over</i> <i>Cardiology</i> , 2018, 121, 1039-1045.	1.6	10
234	The ESC DAPT Guidelines 2017. <i>European Heart Journal</i> , 2018, 39, 187-188.	2.2	14

#	ARTICLE	IF	CITATIONS
235	Determinants of radiation dose during right transradial access: Insights from the RAD-MATRIX study. American Heart Journal, 2018, 196, 113-118.	2.7	7
236	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 68-76.	2.9	28
237	Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC). American Heart Journal, 2018, 198, 152-159.	2.7	24
238	Influence of operator experience and PCI volume on transfemoral access techniques: A collaboration of international cardiovascular societies. Cardiovascular Revascularization Medicine, 2018, 19, 143-150.	0.8	2
239	Impact of Sex on Comparative Outcomes of Radial Versus Femoral Access in Patients With Acute Coronary Syndromes Undergoing Invasive Management. JACC: Cardiovascular Interventions, 2018, 11, 36-50.	2.9	47
240	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2018, 11, 53-65.	2.9	22
241	Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. American Heart Journal, 2018, 196, 105-112.	2.7	80
242	2017 European Society of Cardiology (ESC) focused update on dual antiplatelet therapy in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Journal of Cardio-thoracic Surgery, 2018, 53, 3-4.	1.4	7
243	Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. European Heart Journal, 2018, 39, e1-e33.	2.2	22
244	Special article 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Revista Espanola De Cardiologia (English Ed), 2018, 71, 42.	0.6	29
245	Current Use of Intracoronary Imaging in Interventional Practice Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. Circulation Journal, 2018, 82, 1360-1368.	1.6	31
246	Real-world application of currently available decision models for dual antiplatelet therapy duration in acute coronary syndrome. Journal of Cardiovascular Medicine, 2018, 19, 310-313.	1.5	0
247	Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function. Journal of the American College of Cardiology, 2018, 71, 1289-1291.	2.8	13
248	Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes. Journal of the American College of Cardiology, 2018, 71, 1231-1242.	2.8	32
249	Development and validation of a risk model for long-term mortality after percutaneous coronary intervention: The IDEAS-BIO Study. Catheterization and Cardiovascular Interventions, 2018, 91, 686-695.	1.7	3
250	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2018, 39, 119-177.	2.2	7,100
251	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal, 2018, 39, 213-260.	2.2	2,246
252	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2018, 53, 34-78.	1.4	261

#	ARTICLE	IF	CITATIONS
253	Efficacy and safety of dual antiplatelet therapy after coronary stenting in patients with chronic kidney disease. <i>American Heart Journal</i> , 2018, 197, 103-112.	2.7	9
254	TCT-539 Clinical outcomes in high bleeding risk patients undergoing complex PCI with the Xience everolimus eluting stent: a patient-level pooled analysis from four Xience post-approval trials. <i>Journal of the American College of Cardiology</i> , 2018, 72, B217.	2.8	1
255	TCT-170 Impact of rate of recruitment on all-cause mortality: Insights from the GLOBAL LEADERS all-comers trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, B72-B73.	2.8	0
256	The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 630-646.	1.7	16
257	ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2915-2931.	2.8	273
258	Radial vs femoral access for the prevention of acute kidney injury (AKI) after coronary angiography or intervention: A systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E518-E526.	1.7	43
259	Unselected Use of Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent for Coronary Revascularization. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006741.	3.9	13
260	TCT-112 Patient-oriented clinical outcomes and net adverse cardiovascular event in the Global Leaders trial. <i>Journal of the American College of Cardiology</i> , 2018, 72, B49.	2.8	0
261	The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. <i>Arrhythmia and Electrophysiology Review</i> , 2018, 7, 55.	2.4	96
262	Reply. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1785-1786.	2.9	0
263	Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation: Rationale and design of the ENVISAGE-TAVI AF trial. <i>American Heart Journal</i> , 2018, 205, 63-69.	2.7	62
264	Chronic Thrombocytopenia and Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1869-1871.	2.9	3
265	Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1576-1586.	2.9	43
266	Activated Clotting Time During Unfractionated Heparin-Supported Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1046-1049.	2.9	4
267	Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea. <i>Circulation</i> , 2018, 138, 646-648.	1.6	35
268	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	13.7	180
269	Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006132.	3.9	38
270	Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial. <i>PLoS ONE</i> , 2018, 13, e0201985.	2.5	3

#	ARTICLE	IF	CITATIONS
271	Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. <i>Lancet, The</i> , 2018, 392, 835-848.	13.7	215
272	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet, The</i> , 2018, 392, 940-949.	13.7	555
273	Incidence and impact of renal dysfunction on clinical outcomes after transcatheter aortic valve implantation. <i>International Journal of Cardiology</i> , 2018, 250, 73-79.	1.7	11
274	Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. <i>EuroIntervention</i> , 2018, 13, 1939-1945.	3.2	7
275	A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. <i>EuroIntervention</i> , 2018, 14, 692-699.	3.2	11
276	Current use of intracoronary imaging in interventional practice – Results of a European Association of Percutaneous Cardiovascular Interventions (EAPCI) and Japanese Association of Cardiovascular Interventions and Therapeutics (CVIT) Clinical Practice Survey. <i>EuroIntervention</i> , 2018, 14, e475-e484.	3.2	87
277	Transradial left main PCI is safe and effective. <i>EuroIntervention</i> , 2018, 14, 1073-1075.	3.2	0
278	Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. <i>European Heart Journal</i> , 2017, 38, ehw525.	2.2	164
279	Safety of optical coherence tomography in daily practice: a comparison with intravascular ultrasound. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, jew037.	1.2	47
280	Long-Term Use of Ticagrelor in Patients with Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2017, 19, 2.	2.9	4
281	Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. <i>American Heart Journal</i> , 2017, 184, 81-87.	2.7	95
282	Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients. <i>European Heart Journal</i> , 2017, 38, ehw627.	2.2	138
283	Impact of chronic kidney disease on 2-year clinical outcomes in patients treated with 6-month or 24-month DAPT duration: An analysis from the PRODIGY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, E73-E84.	1.7	18
284	Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. <i>Lancet, The</i> , 2017, 389, 1025-1034.	13.7	840
285	Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2011-2022.	2.8	109
286	Response by Valgimigli and Gargiulo to Letter Regarding Article, "A Critical Appraisal of Aspirin in Secondary Prevention: Is Less More?" <i>Circulation</i> , 2017, 135, e1037-e1038.	1.6	0
287	Rates and predictors of hospital readmission after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2017, 38, 2211-2217.	2.2	54
288	Adverse events while awaiting myocardial revascularization: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 206-217.	1.4	39

#	ARTICLE	IF	CITATIONS
289	Expanded clinical use of everolimus eluting bioresorbable vascular scaffolds for treatment of coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 58-69.	1.7	0
290	The impact of functional vs degenerative mitral regurgitation on clinical outcomes among patients undergoing transcatheter aortic valve implantation. <i>American Heart Journal</i> , 2017, 184, 71-80.	2.7	29
291	Acute Kidney Injury After Radial or Femoral Access for Invasive Acute Coronary Syndrome Management. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2592-2603.	2.8	132
292	DAPT Duration After Drug-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1211-1214.	2.9	3
293	Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts. <i>International Journal of Cardiology</i> , 2017, 243, 150-155.	1.7	23
294	Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. <i>Annals of Internal Medicine</i> , 2017, 167, 17.	3.9	56
295	Radial versus femoral access in patients with acute coronary syndromes with or without ST-segment elevation. <i>European Heart Journal</i> , 2017, 38, 1069-1080.	2.2	52
296	Rationale and design of the Hunting for the off-target properties of Ticagrelor on Endothelial function and other Circulating biomarkers in Humans (HI-TECH) trial. <i>American Heart Journal</i> , 2017, 189, 128-136.	2.7	8
297	Deciding on the Duration of Dual Antiplatelet Therapy—When the Choice Between 2 Evils Is Still Evil. <i>JAMA Cardiology</i> , 2017, 2, 488.	6.1	3
298	Radiation Exposure and Vascular Access in Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2530-2537.	2.8	61
299	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor Inhibiting Therapies. <i>Circulation</i> , 2017, 136, 1955-1975.	1.6	293
300	Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1621-1630.	2.9	19
301	Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies. <i>Drugs</i> , 2017, 77, 1733-1754.	10.9	21
302	Frequency, Timing, and Impact of Access-Site and Non-Access-Site Bleeding on Mortality Among Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1436-1446.	2.9	99
303	Thrombo-embolic prevention after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2017, 38, 3341-3350.	2.2	59
304	Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation. <i>American Journal of Cardiology</i> , 2017, 120, 1460-1466.	1.6	20
305	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 1082.	0.6	189
306	Transfemoral Approach for Coronary Angiography and Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2269-2279.	2.9	32

#	ARTICLE	IF	CITATIONS
307	Long-term Safety and Efficacy of New-Generation Drug-Eluting Stents in Women With Acute Myocardial Infarction. <i>JAMA Cardiology</i> , 2017, 2, 855.	6.1	25
308	Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. <i>International Journal of Cardiology</i> , 2017, 229, 82-89.	1.7	12
309	Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 994-1002.	1.7	9
310	Long-term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main coronary artery: A pooled analysis of the ISAR-LEFTMAIN and ISAR-LEFTMAIN 2 randomized clinical trials. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 1-10.	1.7	4
311	Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled analysis of six randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 178-189.	1.7	18
312	Clinical outcomes of dual antiplatelet therapy after implantation of drug-eluting stents in patients with different cardiovascular risk factors. <i>Clinical Research in Cardiology</i> , 2017, 106, 165-173.	3.3	14
313	Stent and Dual Antiplatelet Therapy Duration Comparisons in the Setting of a Multicenter Randomized Controlled Trial: Can the Operator Experience Affect the Study Results?. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	0
314	Long-term dual antiplatelet therapy and concomitant optimal medical therapy following percutaneous coronary intervention. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, S102-S106.	1.7	1
315	Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle. <i>Journal of Thoracic Disease</i> , 2017, 9, 4260-4265.	1.4	9
316	Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial. <i>EuroIntervention</i> , 2017, 13, 78-86.	3.2	21
317	Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the five-year follow-up of the EXAMINATION trial. <i>EuroIntervention</i> , 2017, 13, e557-e563.	3.2	8
318	Prognostic impact of invasive haemodynamic measurements in combination with clinical and echocardiographic characteristics on two-year clinical outcomes of patients undergoing transcatheter aortic valve implantation. <i>EuroIntervention</i> , 2017, 12, e2186-e2193.	3.2	10
319	State of the art: duration of dual antiplatelet therapy after percutaneous coronary intervention and coronary stent implantation – past, present and future perspectives. <i>EuroIntervention</i> , 2017, 13, 717-733.	3.2	37
320	Atrial Fibrillation on Non-vitamin K Antagonist Oral Anticoagulant Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. , 2017, , 19-38.		0
321	Trans-radial and Trans-femoral Intervention. , 2017, , 9-15.		0
322	Will PIONEER AF-PCI change my practice?. <i>EuroIntervention</i> , 2017, 13, e609-e612.	3.2	0
323	Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. <i>European Heart Journal</i> , 2016, 37, ehv443.	2.2	293
324	11â€¦Predicting the outcome of reperfusion acutely in patients with STEMI – derivation and validation of the ATI score. <i>Heart</i> , 2016, 102, A6.2-A6.	2.9	0

#	ARTICLE	IF	CITATIONS
325	Radial Versus Femoral Access for Coronary Interventions Across the Entire Spectrum of Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1419-1434.	2.9	385
326	A Critical Appraisal of Aspirin in Secondary Prevention. <i>Circulation</i> , 2016, 134, 1881-1906.	1.6	70
327	TCT-475 Effect of Stent Diameter in Women Undergoing Percutaneous Coronary Intervention with Early- and New-Generation Drug-Eluting Stents: From the Women in Innovation and Drug-Eluting Stents (WIN-DES) Collaboration. <i>Journal of the American College of Cardiology</i> , 2016, 68, B191.	2.8	0
328	Role of stent type and of duration of dual antiplatelet therapy in patients with chronic kidney disease undergoing percutaneous coronary interventions. Is bare metal stent implantation still a justifiable choice? A post-hoc analysis of the all comers PRODIGY trial. <i>International Journal of Cardiology</i> , 2016, 212, 110-117.	1.7	26
329	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 674-684.	2.9	51
330	Everolimus-Eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy: the CART (Cardiac Allograft Reparative Therapy) Prospective Multicenter Pilot Study. <i>Journal of Cardiovascular Translational Research</i> , 2016, 9, 40-48.	2.4	9
331	Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials. <i>Clinical Research in Cardiology</i> , 2016, 105, 575-584.	3.3	18
332	Impact of vascular access on acute kidney injury after percutaneous coronary intervention. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 333-338.	0.8	37
333	Digital Gangrene Following Transradial Coronary Angiogram. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 980-981.	2.9	3
334	Efficacy of Radial Versus Femoral Access in the Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 978-979.	2.9	4
335	Bivalirudin Versus Unfractionated Heparin for Acute Coronary Syndromes: Do We Have a Winner?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 721-724.	0.6	0
336	Efficacy and Safety of Dual Antiplatelet Therapy After Complex PCI. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1851-1864.	2.8	319
337	Bivalirudina frente a heparina no fraccionada en sÃndromes coronarios agudos: Â¿hay un vencedor?. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 721-724.	1.2	0
338	Reducing Microvascular Dysfunction in Revascularized Patients with ST-Elevation Myocardial Infarction by Off-Target Properties of Ticagrelor versus Prasugrel. Rationale and Design of the REDUCE-MVI Study. <i>Journal of Cardiovascular Translational Research</i> , 2016, 9, 249-256.	2.4	15
339	Bivalirudin in Current Practice. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1321-1323.	2.9	5
340	Prolonged vs Short Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With or Without Peripheral Arterial Disease. <i>JAMA Cardiology</i> , 2016, 1, 795.	6.1	68
341	Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1780-1789.	2.9	23
342	Response by Costa et al to Letter Regarding Article, "The Rotterdam Radial Access Research: Ultrasound-Based Radial Artery Evaluation for Diagnostic and Therapeutic Coronary Procedures". <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	3.9	0

#	ARTICLE	IF	CITATIONS
343	Phosphate- or Citrate-Buffered Tirofiban Versus Unfractionated Heparin and its Impact on Thrombocytopenia and Clinical Outcomes in Patients With Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2016, 9, 1667-1676.	2.9	8
344	Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization. JACC: Cardiovascular Interventions, 2016, 9, 2280-2288.	2.9	26
345	Association Between Duration of Dual Antiplatelet Therapy and Angiographic Multivessel Disease on Outcomes in Patients Treated With Newer-Generation Drug-Eluting Stents. Circulation: Cardiovascular Interventions, 2016, 9, .	3.9	12
346	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 1890-1901.	2.9	32
347	Bivalirudin or unfractionated heparin in patients with acute coronary syndromes managed invasively with and without ST elevation (MATRIX): randomised controlled trial. BMJ, The, 2016, 354, i4935.	6.0	43
348	Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ, The, 2016, 355, i5483.	6.0	48
349	External validity of the "all-comers" design: insights from the BIOSCIENCE trial. Clinical Research in Cardiology, 2016, 105, 744-754.	3.3	11
350	Percutaneous Coronary Interventions for the Treatment of Stenoses in Small Coronary Arteries. JACC: Cardiovascular Interventions, 2016, 9, 1324-1334.	2.9	63
351	Effect of Diabetes Mellitus on Frequency of Adverse Events in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2016, 118, 345-352.	1.6	16
352	Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study. Catheterization and Cardiovascular Interventions, 2016, 87, 1187-1193.	1.7	7
353	Bivalirudin in Acute Coronary Syndromes. New England Journal of Medicine, 2016, 374, 284-286.	27.0	0
354	A Randomized Comparison of Reservoir-Based Polymer-Free Amphilimus-Eluting Stents Versus Everolimus-Eluting Stents With Durable Polymer in Patients With Diabetes Mellitus. JACC: Cardiovascular Interventions, 2016, 9, 42-50.	2.9	68
355	Effect of Chronic Kidney Disease in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2016, 9, 28-38.	2.9	31
356	The Rotterdam Radial Access Research. Circulation: Cardiovascular Interventions, 2016, 9, e003129.	3.9	59
357	Developing drugs for use before, during and soon after percutaneous coronary intervention. Expert Opinion on Pharmacotherapy, 2016, 17, 803-818.	1.8	14
358	Impact of proton pump inhibitors on clinical outcomes in patients treated with a 6- or 24-month dual-antiplatelet therapy duration: Insights from the PROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia study trial. American Heart Journal, 2016, 174, 95-102.	2.7	53
359	Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. American Heart Journal, 2016, 175, 56-65.	2.7	61
360	Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?. JACC: Cardiovascular Interventions, 2016, 9, 426-436.	2.9	135

#	ARTICLE	IF	CITATIONS
361	Effect of Pre-Hospital Ticagrelor During the First 24 h After Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 646-656.	2.9	31
362	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e002995.	3.9	12
363	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. <i>Lancet, The</i> , 2016, 387, 349-356.	13.7	109
364	Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. <i>Lancet, The</i> , 2016, 387, 357-366.	13.7	174
365	Questions and answers on antithrombotic therapy: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, e1-e7.	2.2	2
366	Questions and answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, e8-e14.	2.2	18
367	Questions and answers on diagnosis and risk assessment: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, e15-e21.	2.2	11
368	EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). <i>European Heart Journal</i> , 2016, 37, 152-160.	2.2	29
369	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	2.2	5,890
370	Dual Antiplatelet Therapy After Drug-eluting Stent Implantation. <i>Interventional Cardiology Review</i> , 2016, 11, 51.	1.6	6
371	A tool for predicting the outcome of reperfusion in ST-elevation myocardial infarction using age, thrombotic burden and index of microcirculatory resistance (ATI score). <i>EuroIntervention</i> , 2016, 12, 1223-1230.	3.2	29
372	Appraising the safety and efficacy profile of left atrial appendage closure in 2016 and the future clinical perspectives. Results of the EAPCI LAAC survey. <i>EuroIntervention</i> , 2016, 12, 112-118.	3.2	4
373	Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study. <i>EuroIntervention</i> , 2016, 12, 30-37.	3.2	21
374	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. <i>EuroIntervention</i> , 2016, 12, e623-e631.	3.2	17
375	Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration. <i>EuroIntervention</i> , 2016, 11, e1222-e1230.	3.2	35
376	Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2016, 12, 1239-1245.	3.2	92
377	Assessing the cardiology community position on transradial intervention and the use of bivalirudin in patients with acute coronary syndrome undergoing invasive management: results of an EAPCI survey. <i>EuroIntervention</i> , 2016, 12, 1154-1163.	3.2	12
378	A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis. <i>EuroIntervention</i> , 2016, 12, e1385-e1394.	3.2	17

#	ARTICLE	IF	CITATIONS
379	How should I treat this unusual anterolateral ST-elevation myocardial infarction with recurrent ventricular fibrillation and cardiac arrest?. <i>EuroIntervention</i> , 2016, 12, 928-932.	3.2	1
380	Radial versus femoral approach in STEMI: what do we know so far?. <i>Minerva Cardioangiologica</i> , 2016, 64, 219-37.	1.2	1
381	Bivalirudin in Acute Coronary Syndromes. Authors reply. <i>New England Journal of Medicine</i> , 2016, 374, 285-6.	27.0	2
382	TCT-379 Independent and Combined Effect of Chronic Kidney Disease and Diabetes Mellitus in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents: Results from a Patient-Level Pooled Analysis of Randomized Controlled Trials. <i>Journal of the American College of Cardiology</i> , 2015, 66, B152.	2.8	0
383	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 1125.	0.6	57
384	Incidence, prognostic impact, and optimal definition of contrast-induced acute kidney injury in consecutive patients with stable or unstable coronary artery disease undergoing percutaneous coronary intervention. insights from the all-comer <scp>PRODIGY</scp> trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, E19-27.	1.7	30
385	Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2015, 114, 933-944.	3.4	11
386	Acute kidney injury after percutaneous coronary intervention: Rationale of the <scp>AKI-MATRIX</scp> (acute kidney injury-minimizing adverse hemorrhagic events by TRansradial access site and systemic) Tj ETQq0 0 0 rgBT /Overlock 10 T 2015, 86, 950-957.	1.7	37
387	Rationale and study design of the <scp>RESERVOIR</scp> trial: A randomized trial comparing reservoir-based polymer-free amphiphilic-eluting stents versus everolimus-eluting stents with durable polymer in patients with diabetes mellitus. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, E116-22.	1.7	8
388	Incremental Value of the CRUSADE, ACUITY, and HAS-BLED Risk Scores for the Prediction of Hemorrhagic Events After Coronary Stent Implantation in Patients Undergoing Long or Short Duration of Dual Antiplatelet Therapy. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	59
389	Perspectives on the 2014 ESC/EACTS Guidelines on Myocardial Revascularization. <i>Journal of Cardiovascular Translational Research</i> , 2015, 8, 211-220.	2.4	16
390	Effectiveness of Pretreatment With Dual Oral Antiplatelet Therapy. <i>American Journal of Cardiology</i> , 2015, 116, 660-668.	1.6	7
391	Long-Term Safety of Drug-Eluting and Bare-Metal Stents. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2496-2507.	2.8	396
392	Radial versus femoral access for cardiac catheterisation - Authors' reply. <i>Lancet, The</i> , 2015, 386, 2394.	13.7	10
393	2014 ESC/EACTS Guidelines on Myocardial Revascularization. <i>Revista Espanola De Cardiologia (English) Tj ETQq1 1,0,784314 rgBT /Ove</i>	0,6	26
394	Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial. <i>European Heart Journal</i> , 2015, 36, 1242-1251.	2.2	76
395	Zotarolimus-Eluting Versus Bare-Metal Stents in Uncertain Drug-Eluting Stent Candidates. <i>Journal of the American College of Cardiology</i> , 2015, 65, 805-815.	2.8	248
396	Current-era biovascular scaffolds seen by experts: An experience-based survey. <i>International Journal of Cardiology</i> , 2015, 188, 16-18.	1.7	5

#	ARTICLE	IF	CITATIONS
397	Does smoking habit affect the randomized comparison of 6 versus 24-month dual antiplatelet therapy duration? Insights from the PRODIGY trial. <i>International Journal of Cardiology</i> , 2015, 190, 242-245.	1.7	5
398	Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris) on Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2015, 116, 845-852.	1.6	32
399	Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?. <i>European Heart Journal</i> , 2015, 36, 1219-1222.	2.2	29
400	Bleeding and stent thrombosis on P2Y ₁₂ -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , 2015, 36, 1762-1771.	2.2	297
401	Anatomic Characteristics and Clinical Implications of Angiographic Coronary Thrombus. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	3.9	11
402	Current status of clinically available bioresorbable scaffolds in percutaneous coronary interventions. <i>Netherlands Heart Journal</i> , 2015, 23, 153-160.	0.8	16
403	Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. <i>BMJ</i> , 2015, 350, h1618-h1618.	6.0	279
404	Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. <i>Lancet</i> , 2015, 385, 2465-2476.	13.7	1,043
405	Bivalirudin versus heparin in patients with acute myocardial infarction: A meta-analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 378-389.	1.7	14
406	Short- Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1092-1102.	2.8	163
407	Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5433 patients enrolled in contemporary coronary stent trials. <i>International Journal of Cardiology</i> , 2015, 187, 111-115.	1.7	26
408	Cardiac Nerve Growth Factor Overexpression Induces Bone Marrow-derived Progenitor Cells Mobilization and Homing to the Infarcted Heart. <i>Molecular Therapy</i> , 2015, 23, 1854-1866.	8.2	14
409	Angiographic and Optical Coherence Tomography Insights Into Bioresorbable Scaffold Thrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	3.9	90
410	Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 373, 997-1009.	27.0	334
411	Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1203-1204.	2.8	8
412	TCT-425 Rotterdam Radial Access Research: Radial Artery Access Evaluation After Coronary Procedures With Very High Resolution Ultrasound; The Puncture's Footprint. <i>Journal of the American College of Cardiology</i> , 2015, 66, B173.	2.8	0
413	TCT-272 Everolimus-eluting stent versus bare-metal stent in diabetic patients with ST-segment elevation myocardial infarction. Insights from the EXAMINATION trial. <i>Journal of the American College of Cardiology</i> , 2015, 66, B107.	2.8	0
414	Impact of greater than 12-month dual antiplatelet therapy duration on mortality: Drug-specific or a class-effect? A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 201, 179-181.	1.7	26

#	ARTICLE	IF	CITATIONS
415	Comprehensive Meta-Analysis of Safety and Efficacy of Bivalirudin Versus Heparin With or Without Routine Glycoprotein IIb/IIIa Inhibitors in Patients With Acute Coronary Syndrome. JACC: Cardiovascular Interventions, 2015, 8, 201-213.	2.9	69
416	Current know how on the absorb BVS technology: An experts' survey. International Journal of Cardiology, 2015, 180, 203-205.	1.7	11
417	Everolimus-eluting stent versus bare-metal stent in elderly (>=75years) versus non-elderly (<75years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the examination trial. International Journal of Cardiology, 2015, 179, 73-78.	1.7	17
418	Benefit of radial approach in reducing the incidence of acute kidney injury after percutaneous coronary intervention: A meta-analysis of 22,108 patients. International Journal of Cardiology, 2015, 179, 309-311.	1.7	25
419	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 386-386.	1.0	46
420	Coronary stent selection and optimal course of dual antiplatelet therapy in patients at high bleeding or thrombotic risk. Current Opinion in Cardiology, 2015, 30, 325-332.	1.8	8
421	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. EuroIntervention, 2015, 10, 1015-1021.	3.2	21
422	Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey. EuroIntervention, 2015, 11, 68-74.	3.2	48
423	European expert consensus on rotational atherectomy. EuroIntervention, 2015, 11, 30-36.	3.2	247
424	Antithrombotic therapy in TAVI patients: changing concepts. EuroIntervention, 2015, 14, W92-W95.	3.2	23
425	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. EuroIntervention, 2015, 10, 1095-1108.	3.2	29
426	2014 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention, 2015, 10, 1024-1094.	3.2	251
427	Optical coherence tomography appraisal of residual thrombus burden in patients with ST-segment elevation myocardial infarction undergoing intraprocedural versus post-stenting prolonged bivalirudin infusion. Rationale and design of the MATRIX (Minimizing Adverse Haemorrhagic Events by) Tj ETQq1 1 0:784314 6gBT /Ov	3.2	0
428	Rapid exchange ultra-thin microcatheter using fibre-optic sensing technology for measurement of intracoronary fractional flow reserve. EuroIntervention, 2015, 11, 428-432.	3.2	27
429	Radial and Femoral Access in Percutaneous Intervention. , 2015, , 361-371.		0
430	Time for science to catch up with clinical practice?. Journal of Thoracic Disease, 2015, 7, E603-6.	1.4	2
431	Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. Thrombosis and Haemostasis, 2014, 112, 883-891.	3.4	27
432	ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome. European Heart Journal Supplements, 2014, 16, C2-C28.	0.1	2

#	ARTICLE	IF	CITATIONS
433	Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. <i>BMJ, The</i> , 2014, 349, g6427-g6427.	6.0	82
434	Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. <i>Heart</i> , 2014, 100, 1158-1164.	2.9	216
435	2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 517-592.	1.4	2,164
436	Shifting the Focus to Recurrences. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1114-1116.	2.9	2
437	Comparison of Bivalirudin Versus Heparin(s) During Percutaneous Coronary Interventions in Patients Receiving Prasugrel: A Propensity-Matched Study. <i>Clinical Cardiology</i> , 2014, 37, 14-20.	1.8	3
438	Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program. <i>American Heart Journal</i> , 2014, 168, 838-845.e6.	2.7	47
439	Pretreatment With P2Y ₁₂ Inhibitors in Non-ST-Segment Elevation Acute Coronary Syndrome Is Clinically Justified. <i>Circulation</i> , 2014, 130, 1891-1903.	1.6	39
440	Acute kidney injury after primary angioplasty. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 60-67.	1.5	14
441	Randomized comparison of operator radiation exposure comparing transradial and transfemoral approach for percutaneous coronary procedures: rationale and design of the minimizing adverse haemorrhagic events by TRansradial access site and systemic implementation of angioX Radiation Dose study (RAD-MATRIX). <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 209-213.	0.8	17
442	Excimer Laser LEsion Modification to Expand Non-dilatable sTents: The ELLEMENT Registry. <i>Cardiovascular Revascularization Medicine</i> , 2014, 15, 8-12.	0.8	122
443	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 354-361.	2.9	45
444	Comparison of Percutaneous Coronary Intervention (With Drug-Eluting Stents) Versus Coronary Artery Bypass Grafting in Women With Severe Narrowing of the Left Main Coronary Artery (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf Cardiology, 2014, 113, 1348-1355.	1.8	14
445	Short- Versus Long-Term Duration of Dual Antiplatelet Therapy in Patients Treated for In-Stent Restenosis. <i>Journal of the American College of Cardiology</i> , 2014, 63, 506-512.	2.8	58
446	Two-Year Outcomes After First- or Second-Generation Drug-Eluting or Bare-Metal Stent Implantation in All-Comer Patients Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 20-28.	2.9	124
447	Scientific Foundation and Possible Implications for Practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX (MATRIX) Trial. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 101-111.	2.4	42
448	Comparison of Newer-Generation Drug-Eluting With Bare-Metal Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 55-63.	2.9	96
449	Transradial Coronary Catheterization and Intervention Across the Whole Spectrum of Allen Test Results. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1833-1841.	2.8	123
450	Prospective validation of the Bleeding Academic Research Consortium classification in the all-comer PRODIGY trial. <i>European Heart Journal</i> , 2014, 35, 2524-2529.	2.2	49

#	ARTICLE	IF	CITATIONS
451	How can we optimize the processes of care for acute coronary syndromes to improve outcomes?. American Heart Journal, 2014, 168, 622-631.e2.	2.7	16
452	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	2.2	4,141
453	Usefulness and Safety of Vorapaxar in Patients With Nonâ€“ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention (from the TRACER Trial). American Journal of Cardiology, 2014, 114, 665-673.	1.6	17
454	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. European Heart Journal, 2014, 35, 3155-3179.	2.2	490
455	The EXAMINATION Trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation) Tj ETQq1 1 0,784314 rgBT /Overl	2.9	80
456	Stable Angina Pectoris. Current Atherosclerosis Reports, 2014, 16, 422.	4.8	19
457	Longâ€“term outcome in patients with ST segment elevation myocardial infarction and multivessel disease treated with culpritâ€“only, immediate, or staged multivessel percutaneous revascularization strategies: Insights from the REAL registry. Catheterization and Cardiovascular Interventions, 2014, 84, 912-922.	1.7	46
458	Randomized comparison between 3-month Cre8 DES vs. 1-month Vision/Multilink8 BMS neointimal coverage assessed by OCT evaluation: The DEMONSTRATE study. International Journal of Cardiology, 2014, 176, 904-909.	1.7	31
459	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. Europace, 2014, 16, 1655-1673.	1.7	105
460	Antiplatelet and anticoagulation agents in acute coronary syndromes: What is the current status and what does the future hold?. American Heart Journal, 2014, 168, 611-621.	2.7	34
461	Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ, The, 2014, 348, g3859-g3859.	6.0	291
462	Two-year outcomes after first- or second-generation drug-eluting stent implantation in patients with in-stent restenosis. A PRODIGY trial substudy. International Journal of Cardiology, 2014, 173, 343-345.	1.7	7
463	Predicting 3-Year Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2014, 7, 464-470.	2.9	50
464	Optimization in Stent Implantation by Manual Thrombus Aspiration in ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2014, 7, 294-300.	3.9	30
465	68â€“...Predicting 3-Year Mortality After PCI: Revised Clinical Syntax Model Based on Patient Level Data from 7 Contemporary Stent Trials. Heart, 2014, 100, A38.2-A39.	2.9	0
466	The conundrum of antithrombotic drugs before, during and after primary PCI. EuroIntervention, 2014, 10, T64-T73.	3.2	9
467	Meeting the Unmet â€“ The Cre8 Polymer-free Drug-eluting Stents Technology. Interventional Cardiology Review, 2014, 9, 184.	1.6	1
468	Abstract 12930: Neutrophil Extracellular Traps Correlate With Impaired Myocardial Reperfusion in Patients With St Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention. Circulation, 2014, 130, .	1.6	0

#	ARTICLE	IF	CITATIONS
469	Outcome of patients on oral anticoagulation undergoing coronary artery stenting: data from discharge to 12 months in the Warfarin and Coronary Stenting (WAR-STENT) Registry. <i>Journal of Invasive Cardiology</i> , 2014, 26, 563-9.	0.4	24
470	Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 737-745.	2.9	54
471	TCT-447 Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction. Insights from the EXAMINATION trial. <i>Journal of the American College of Cardiology</i> , 2013, 62, B138.	2.8	0
472	TCT-242 Impact of gender on clinical outcome of everolimus-eluting stent versus bare-metal stent in patients with ST-elevation myocardial infarction.. <i>Journal of the American College of Cardiology</i> , 2013, 62, B79-B80.	2.8	0
473	Zotarolimus- Versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2075-2082.	2.8	69
474	Open-Label, Randomized, Placebo-Controlled Evaluation of Intracoronary Adenosine or Nitroprusside After Thrombus Aspiration During Primary Percutaneous Coronary Intervention for the Prevention of Microvascular Obstruction in Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 580-589.	2.9	100
475	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected Left Main Coronary Artery. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1242-1249.	2.9	75
476	Incidence and Outcome of High On-Treatment Platelet Reactivity in Patients With Non-ST Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the VIP) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 462 T</i> 792-798.	1.6	12
477	Five-year outcomes of surgical or percutaneous myocardial revascularization in diabetic patients. <i>International Journal of Cardiology</i> , 2013, 168, 1028-1033.	1.7	19
478	Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. <i>Lancet, The</i> , 2013, 382, 1879-1888.	13.7	127
479	Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2013, 166, 119-126.e1.	2.7	5
480	Benefits and risks of long-term duration of dual antiplatelet therapy after drug-eluting stenting: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2013, 168, 2579-2587.	1.7	39
481	Predictors and clinical implications of stent thrombosis in patients with ST-segment elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2013, 168, 2632-2636.	1.7	11
482	Clinical Outcomes With Drug-Eluting and Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 62, 496-504.	2.8	210
483	Three-year follow-up of the MULTICentre evaluation of Single high-dose Bolus Tirofiban versus Abciximab with Sirolimus-eluting STent or Bare-Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY). <i>International Journal of Cardiology</i> , 2013, 165, 134-141.	1.7	29
484	Effects of pre-hospital clopidogrel administration on early and late residual platelet reactivity in ST-segment elevation myocardial infarction patients undergoing primary intervention. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 192-194.	3.8	19
485	Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2013, 167, 2140-2148.	1.7	113
486	A prospective, randomized trial of intravascular-ultrasound guided compared to angiography guided stent implantation in complex coronary lesions: The AVIO trial. <i>American Heart Journal</i> , 2013, 165, 65-72.	2.7	212

#	ARTICLE	IF	CITATIONS
487	Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: Rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in Uncertain DES Candidates study. <i>American Heart Journal</i> , 2013, 166, 831-838.	2.7	18
488	2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.	2.2	3,915
489	Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). <i>European Heart Journal</i> , 2013, 34, 909-919.	2.2	108
490	Identifying responsiveness to oral P2Y12 receptor blockers. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, S8-S15.	1.5	4
491	Migratory activity of circulating progenitor cells and serum SDF-1 β predict adverse events in patients with myocardial infarction. <i>Cardiovascular Research</i> , 2013, 100, 192-200.	3.8	31
492	Deferred angioplasty and stenting in primary percutaneous coronary intervention: one step back, two steps forward?. <i>EuroIntervention</i> , 2013, 8, 1119-1123.	3.2	4
493	Stent-related defects in patients presenting with stent thrombosis: differences at optical coherence tomography between subacute and late/very late thrombosis in the Mechanism Of Stent Thrombosis (MOST) study. <i>EuroIntervention</i> , 2013, 9, 936-944.	3.2	53
494	Quantification of scientific output in cardiovascular medicine: a perspective based on global data. <i>EuroIntervention</i> , 2013, 9, 975-978.	3.2	4
495	In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry. <i>Journal of Invasive Cardiology</i> , 2013, 25, 170-6.	0.4	8
496	Role for Substance P α -Based Nociceptive Signaling in Progenitor Cell Activation and Angiogenesis During Ischemia in Mice and in Human Subjects. <i>Circulation</i> , 2012, 125, 1774-1786.	1.6	90
497	Letter by Cortese and Valgimigli Regarding Article, "Antithrombotic Therapy in Patients With Chronic Kidney Disease". <i>Circulation</i> , 2012, 126, e333; author reply e334.	1.6	0
498	Peri-procedural myocardial infarction and troponin: a quick journey through the land of confusion. <i>Heart</i> , 2012, 98, 1400-1401.	2.9	4
499	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	2.2	5,034
500	Comparison of drug-eluting stents with bare metal stents in patients with ST-segment elevation myocardial infarction. <i>European Heart Journal</i> , 2012, 33, 977-987.	2.2	134
501	Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting. <i>Circulation</i> , 2012, 125, 2015-2026.	1.6	640
502	Letter by Vranckx and Valgimigli Regarding Article, "Validation of the Bleeding Academic Research Consortium Definition of Bleeding in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention". <i>Circulation</i> , 2012, 126, e276; author reply e277.	1.6	0
503	Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2012, 366, 20-33.	27.0	701
504	Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. <i>Lancet</i> , 2012, 380, 1482-1490.	13.7	412

#	ARTICLE	IF	CITATIONS
505	Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study trial. <i>American Heart Journal</i> , 2012, 163, 104-111.	2.7	13
506	Assessing the role of eptifibatid in patients with diffuse coronary disease undergoing drug-eluting stenting: The INtegrilin plus STenting to Avoid myocardial Necrosis Trial. <i>American Heart Journal</i> , 2012, 163, 835.e1-835.e7.	2.7	11
507	Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2012, 155, 243-248.	1.7	5
508	Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. <i>European Heart Journal</i> , 2012, 33, 3098-3104.	2.2	138
509	Transradial Versus Transfemoral Intervention for Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 23-35.	2.9	101
510	Prasugrel Versus Tirofiban Bolus With or Without Short Post-Bolus Infusion With or Without Concomitant Prasugrel Administration in Patients With Myocardial Infarction Undergoing Coronary Stenting. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 268-277.	2.9	162
511	Drug-Eluting Stent for Left Main Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 718-727.	2.9	121
512	Does the site of bleeding matter? A stratified analysis on Location of TIMI-graded bleedings and their impact on 12-month outcome in patients with ST-segment elevation myocardial infarction. <i>EuroIntervention</i> , 2012, 8, 71-78.	3.2	25
513	Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study. <i>EuroIntervention</i> , 2012, 8, 486-492.	3.2	1
514	Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2474-2483.	2.8	315
515	Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1945-1954.	2.8	383
516	Triple Antiplatelet Therapy in Acute Coronary Syndromes. <i>Drugs</i> , 2011, 71, 1703-1719.	10.9	13
517	Genetic determinants of on-clopidogrel high platelet reactivity. <i>Platelets</i> , 2011, 22, 399-407.	2.3	48
518	Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes. <i>International Journal of Cardiology</i> , 2011, 150, 325-331.	1.7	129
519	Relationship between paraoxonase Q192R gene polymorphism and on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2106-2108.	3.8	29
520	Early Angio-Guided Complete Revascularization versus Culprit Vessel PCI Followed by Ischemia-Guided Staged PCI in STEMI Patients with Multivessel Disease. <i>Journal of Interventional Cardiology</i> , 2011, 24, 535-541.	1.2	28
521	Different clinical models of CD34 ⁺ cells mobilization in patients with cardiovascular disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2011, 32, 1-8.	2.1	12
522	Persistent Coronary No Flow After Wire Insertion Is an Early and Readily Available Mortality Risk Factor Despite Successful Mechanical Intervention in Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 51-62.	2.9	29

#	ARTICLE	IF	CITATIONS
523	Prediction of 1-Year Clinical Outcomes Using the SYNTAX Score in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 66-75.	2.9	132
524	Incidence, Prognostic Impact, and Influence of Antithrombotic Therapy on Access and Nonaccess Site Bleeding in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 191-197.	2.9	229
525	A Patient-Level Pooled Analysis Assessing the Impact of the SYNTAX (Synergy Between Percutaneous) Tj ETQq1 1 0.784314 rgBT /Over Patients Enrolled in Contemporary Coronary Stent Trials. JACC: Cardiovascular Interventions, 2011, 4, 645-653.	2.9	70
526	Dual antiplatelet therapy duration. Current Opinion in Cardiology, 2011, 26, S4-S14.	1.8	5
527	Clinical dilemmas on managing antiplatelet therapies after percutaneous coronary intervention. Current Opinion in Cardiology, 2011, 26, S1-S3.	1.8	0
528	Standardized Bleeding Definitions for Cardiovascular Clinical Trials. Circulation, 2011, 123, 2736-2747.	1.6	3,378
529	Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II). Circulation, 2011, 124, 1260-1269.	1.6	217
530	Looking back into the future: desirudin in acute coronary syndromes and coronary stenting. EuroIntervention, 2011, 7, 263-269.	3.2	1
531	Percutaneous coronary intervention versus bypass surgery for left main coronary artery disease: a meta-analysis of randomised trials. EuroIntervention, 2011, 7, 738-746.	3.2	26
532	Cardiovascular risk profile of patients included in stent trials; a pooled analysis of individual patient data from randomised clinical trials: insights from 33 prospective stent trials in Europe. EuroIntervention, 2011, 7, 859-871.	3.2	4
533	Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. EuroIntervention, 2011, 7, 977-984.	3.2	41
534	AMI on the move. EuroIntervention, 2011, 7, 415-419.	3.2	0
535	Latest Clinical Data on Testing for High On-Treatment Platelet Reactivity. Reviews in Cardiovascular Medicine, 2011, 12, 14-22.	1.4	9
536	Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clinical Research in Cardiology, 2010, 99, 345-357.	3.3	34
537	Poor response to clopidogrel: current and future options for its management. Journal of Thrombosis and Thrombolysis, 2010, 30, 319-331.	2.1	53
538	Long-Term Clinical Results Following Stenting of the Left Main Stem. JACC: Cardiovascular Interventions, 2010, 3, 584-594.	2.9	49
539	Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting. Journal of Thrombosis and Haemostasis, 2010, 8, 1903-1911.	3.8	14
540	Boosting platelet inhibition in poor responder to aspirin and clopidogrel undergoing percutaneous coronary intervention: role of tirofiban. Journal of Blood Medicine, 2010, 1, 61.	1.7	2

#	ARTICLE	IF	CITATIONS
541	Response to Letter Regarding Article, a€œIntensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention: Results From the Double-Blind, Prospective, Randomized Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel Studyâ€. <i>Circulation</i> , 2010, 121,	1.6	0
542	Tailored Medical and Interventional Therapy Against Recurrent Stent Thrombosis After Drug-Eluting Stenting. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2010, 16, 591-593.	1.7	5
543	Comparison of the Long-Term Safety and Efficacy of Drug-Eluting and Bare-Metal Stent Implantation in Saphenous Vein Grafts. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 249-256.	3.9	17
544	What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2010, 103, 367-377.	0.5	9
545	Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention: a meta-analysis of randomized trials. <i>European Heart Journal</i> , 2010, 31, 35-49.	2.2	103
546	Safety evaluation of tirofiban. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 801-819.	2.4	6
547	Evaluation of Platelet Inhibition by Tirofiban in Patients Stratified According to Aspirin and Clopidogrel Responsiveness. <i>Journal of the American College of Cardiology</i> , 2010, 55, 255-256.	2.8	16
548	Long-Term Clinical Outcome Based on Aspirin and Clopidogrel Responsiveness Status After Elective Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1447-1455.	2.8	118
549	Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2010, 160, 804-811.	2.7	66
550	Antiplatelet and antithrombotic treatment after primary percutaneous coronary intervention: Balancing safety and efficacy. <i>American Heart Journal</i> , 2010, 160, S36-S41.	2.7	6
551	Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update. <i>EuroIntervention</i> , 2010, 6, 39-45.	3.2	5
552	Temporal and Genotype-Driven Variation of Factor VII Levels in Patients With Acute Myocardial Infarction. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2009, 15, 119-122.	1.7	3
553	Assisted circulation using the TandemHeartÂ® during very highâ€risk PCI of the unprotected left main coronary artery in patients declined for CABG. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 302-310.	1.7	36
554	Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 200-210.	2.1	24
555	Longâ€term outcome after percutaneous coronary intervention in patients with essential thrombocythemia. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1235-1238.	3.8	8
556	Intensifying Platelet Inhibition With Tirofiban in Poor Responders to Aspirin, Clopidogrel, or Both Agents Undergoing Elective Coronary Intervention. <i>Circulation</i> , 2009, 119, 3215-3222.	1.6	213
557	Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2009, 133, 213-222.	1.7	89
558	Impact of drug-eluting stent selection on long-term clinical outcomes in patients treated for unprotected left main coronary artery disease: The sirolimus vs paclitaxel drug-eluting stent for left main registry (SP-DELFT). <i>International Journal of Cardiology</i> , 2009, 137, 16-21.	1.7	17

#	ARTICLE	IF	CITATIONS
559	The 5-Year Clinical Outcomes After a Randomized Comparison of Sirolimus-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1900-1901.	2.8	38
560	Drug-Eluting Stents Versus Bare-Metal Stents in Diabetic Patients With ST-Segment Elevation Acute Myocardial Infarction: A Pooled Analysis of Individual Patient Data From 7 Randomized Trials. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 354-364.	0.6	10
561	Defining the Role of Platelet Glycoprotein Receptor Inhibitors in STEMI. <i>Drugs</i> , 2009, 69, 85-100.	10.9	22
562	Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, 585-592.	1.5	8
563	Stent choice in primary percutaneous coronary intervention: drug-eluting stents or bare metal stents?. <i>Journal of Cardiovascular Medicine</i> , 2009, 10, S17-S26.	1.5	5
564	Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R). Rationale for the Study and Protocol Design. <i>Cardiovascular Drugs and Therapy</i> , 2008, 22, 313-320.	2.6	25
565	Prognostic value of serial platelet reactivity measurements on long-term clinical outcome in patients with ST-elevation myocardial infarction undergoing primary PCI. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1824-1826.	3.8	15
566	Effects of Percutaneous Transluminal Septal Myocardial Ablation for Obstructive Hypertrophic Cardiomyopathy on Systolic and Diastolic Left Ventricular Function Assessed by Pressure-Volume Loops. <i>American Journal of Cardiology</i> , 2008, 101, 1179-1184.	1.6	15
567	Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor for Myocardial Recovery After Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1429-1437.	2.8	136
568	Longest Available Clinical Outcomes After Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2212-2219.	2.8	160
569	Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Disease: The Endless Debate. <i>Journal of the American College of Cardiology</i> , 2008, 52, 582-584.	2.8	6
570	Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: a multicentre registry. <i>European Heart Journal</i> , 2008, 29, 2108-2115.	2.2	99
571	A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. <i>International Journal of Cardiology</i> , 2008, 128, 53-61.	1.7	1
572	A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. <i>American Heart Journal</i> , 2008, 155, 274-283.	2.7	170
573	Use of granulocyte colony-stimulating factor during acute MI: Fact or fiction?. <i>Journal of Molecular and Cellular Cardiology</i> , 2008, 44, 436.	1.9	0
574	Cardiovascular events and re-stenosis following administration of G-CSF in acute myocardial infarction: systematic review and meta-analysis. <i>Heart</i> , 2008, 94, 610-616.	2.9	33
575	From bone marrow to the arterial wall: the ongoing tale of endothelial progenitor cells. <i>European Heart Journal</i> , 2008, 30, 890-899.	2.2	143
576	Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after myocardial infarction. <i>European Heart Journal Supplements</i> , 2008, 10, K27-K34.	0.1	4

#	ARTICLE	IF	CITATIONS
577	Carotid Stent Cell Design: Lack of Benefit or Lack of Evidence?. Stroke, 2008, 39, e130; author reply e133.	2.0	7
578	Comparison of Angioplasty With Infusion of Tirofiban or Abciximab and With Implantation of Sirolimus-Eluting or Uncoated Stents for Acute Myocardial Infarction_{title}>The MULTISTRATEGY Randomized Trial</sub>>. JAMA - Journal of the American Medical Association, 2008, 299, 1788.	7.4	245
579	A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. Journal of Cardiovascular Medicine, 2008, Publish Ahead of Print, .	1.5	0
580	A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. Journal of Cardiovascular Medicine, 2008, 9, 957-962.	1.5	4
581	Abciximab: a reappraisal of its use in coronary care. Biologics: Targets and Therapy, 2008, 2, 29.	3.2	8
582	The heart of coronary arteries. European Heart Journal, 2007, 28, 2063-2063.	2.2	0
583	Effect of perindopril on coronary remodelling: insights from a multicentre, randomized study. European Heart Journal, 2007, 28, 2326-2331.	2.2	37
584	Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. European Heart Journal, 2007, 28, 2706-2713.	2.2	337
585	Keeping a high standard in quantitative analyses, meta-analyses, and systematic reviews. European Heart Journal, 2007, 28, 516-517.	2.2	2
586	Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. New England Journal of Medicine, 2007, 356, 1030-1039.	27.0	1,182
587	Favorable Long-Term Outcome After Drug-Eluting Stent Implantation in Nonbifurcation Lesions That Involve Unprotected Left Main Coronary Artery. Circulation, 2007, 116, 158-162.	1.6	182
588	Acute effects of alcohol septal ablation on systolic and diastolic left ventricular function in patients with hypertrophic obstructive cardiomyopathy. Heart, 2007, 94, 1318-1322.	2.9	23
589	Acute coronary syndromes: an emphasis shift from treatment to prevention; and the enduring challenge of vulnerable plaque detection in the cardiac catheterization laboratory. Journal of Cardiovascular Medicine, 2007, 8, 221-229.	1.5	10
590	Benefits of clopidogrel in patients undergoing coronary stenting significantly depend on loading dose: Evidence from a meta-regression. American Heart Journal, 2007, 153, 587-593.	2.7	16
591	Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction. American Heart Journal, 2007, 154, 39-45.	2.7	15
592	Direct and indirect comparison meta-analysis demonstrates the superiority of sirolimus- versus paclitaxel-eluting stents across 5854 patients. International Journal of Cardiology, 2007, 114, 104-105.	1.7	21
593	Plaque sealing: Are the benefits outweighing the risks?. International Journal of Cardiology, 2007, 115, 265-266.	1.7	1
594	Plaque Composition in the Left Main Stem Mimics the Distal But Not the Proximal Tract of the Left Coronary Artery. Journal of the American College of Cardiology, 2007, 49, 23-31.	2.8	51

#	ARTICLE	IF	CITATIONS
595	Impact of Stable Versus Unstable Coronary Artery Disease on 1-Year Outcome in Elective Patients Undergoing Multivessel Revascularization With Sirolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2007, 49, 431-441.	2.8	30
596	Clinical Implications of the PROTECT-TIMI-30 Trial. <i>Journal of the American College of Cardiology</i> , 2007, 49, 729-730.	2.8	1
597	Two-Year Clinical Follow-Up After Sirolimus-Eluting Versus Bare-Metal Stent Implantation Assisted by Systematic Glycoprotein IIb/IIIa Inhibitor Infusion in Patients With Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 138-145.	2.8	78
598	Poor Responsiveness to Clopidogrel: Drug-Specific or Class-Effect Mechanism?. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1132-1137.	2.8	82
599	Factor XIII A-V34L and Factor XIII B-H95R Gene Variants: Effects on Survival in Myocardial Infarction Patients. <i>Molecular Medicine</i> , 2007, 13, 112-120.	4.4	32
600	Cyphering the Complexity of Coronary Artery Disease Using the Syntax Score to Predict Clinical Outcome in Patients With Three-Vessel Lumen Obstruction Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2007, 99, 1072-1081.	1.6	269
601	Interventional Conflicts of interest: Dr. Angiolillo is a consultant and on the speaker's bureau for Bristol Myers Squibb, New York, New York, and Sanofi-Aventis, Paris, France. Dr. Biondi-Zoccai has consulted for Boston Scientific, Natick, Massachusetts, and Cordis, Miami, Florida, and received lecture fees from Bristol Myers Squibb. Dr. Montalescot has been a consultant for and/or received	1.6	110
602	Revisiting the incidence and temporal distribution of cardiac and sudden death in patients undergoing elective intervention for unprotected left main coronary artery stenosis in the drug eluting stent era. <i>EuroIntervention</i> , 2007, 2, 435-43.	3.2	6
603	Sirolimus-Eluting Versus Paclitaxel-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2006, 47, 507-514.	2.8	100
604	Noninvasive Detection of Subclinical Coronary Atherosclerosis Coupled With Assessment of Changes in Plaque Characteristics Using Novel Invasive Imaging Modalities. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1134-1142.	2.8	112
605	Plaque Composition and its Relationship With Acknowledged Shear Stress Patterns in Coronary Arteries. <i>Journal of the American College of Cardiology</i> , 2006, 47, 884-885.	2.8	65
606	Distal Left Main Coronary Disease Is a Major Predictor of Outcome in Patients Undergoing Percutaneous Intervention in the Drug-Eluting Stent Era. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1530-1537.	2.8	181
607	Long-Term Outcomes After Stenting of Bifurcation Lesions With the "Crush" Technique. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1949-1958.	2.8	228
608	Value of Platelet Reactivity in Predicting Response to Treatment and Clinical Outcome in Patients Undergoing Primary Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2178-2185.	2.8	140
609	Persistence of Neointimal Growth 12 Months After Intervention and Occurrence of Delayed Restenosis in Patients With Left Main Coronary Artery Disease Treated With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1491-1494.	2.8	20
610	Diagnostic Performance of Multislice Spiral Computed Tomography of Coronary Arteries as Compared With Conventional Invasive Coronary Angiography. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1896-1910.	2.8	439
611	Clinical effectiveness of bare-metal stenting compared with balloon angioplasty in total coronary occlusions: Insights from a systematic overview of randomized trials in light of the drug-eluting stent era. <i>American Heart Journal</i> , 2006, 151, 682-689.	2.7	41
612	Coronary plaque composition of nonculprit lesions, assessed by in vivo intracoronary ultrasound radio frequency data analysis, is related to clinical presentation. <i>American Heart Journal</i> , 2006, 151, 1020-1024.	2.7	87

#	ARTICLE	IF	CITATIONS
613	In vivo relationship between compositional and mechanical imaging of coronary arteries. <i>American Heart Journal</i> , 2006, 151, 1025.e1-1025.e6.	2.7	14
614	Single-vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug-eluting stenting era. Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registries. <i>American Heart Journal</i> , 2006, 152, 896-902.	2.7	57
615	Reproducibility of intravascular ultrasound radiofrequency data analysis: implications for the design of longitudinal studies. <i>International Journal of Cardiovascular Imaging</i> , 2006, 22, 621-631.	1.5	59
616	Drawbacks of Nonrandomized Trials in Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2006, 97, 151.	1.6	0
617	Is Late Luminal Loss an Accurate Predictor of the Clinical Effectiveness of Drug-Eluting Stents in the Coronary Arteries?. <i>American Journal of Cardiology</i> , 2006, 97, 603-605.	1.6	26
618	Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: Analysis from the SPIRIT FIRST trial. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 67, 188-197.	1.7	26
619	Distance from the ostium as an independent determinant of coronary plaque composition in vivo: an intravascular ultrasound study based radiofrequency data analysis in humans. <i>European Heart Journal</i> , 2006, 27, 655-663.	2.2	68
620	Intramyocardial injection of skeletal myoblasts: long-term follow-up with pressure-volume loops. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2006, 3, S94-S100.	3.3	34
621	Compliance with QUOROM and quality of reporting of overlapping meta-analyses on the role of acetylcysteine in the prevention of contrast associated nephropathy: case study. <i>BMJ: British Medical Journal</i> , 2006, 332, 202-209.	2.3	135
622	Global characterization of coronary plaque rupture phenotype using three-vessel intravascular ultrasound radiofrequency data analysis. <i>European Heart Journal</i> , 2006, 27, 1921-1927.	2.2	71
623	Tirofiban: a critical reappraisal of the clinical use, recent developments and future perspectives. <i>Future Cardiology</i> , 2006, 2, 17-27.	1.2	2
624	Stress and tissue Doppler echocardiographic evidence of effectiveness of myoblast transplantation in patients with ischaemic heart failure. <i>European Journal of Heart Failure</i> , 2006, 8, 641-648.	7.1	28
625	Tissue Factor and Coagulation Factor VII Levels During Acute Myocardial Infarction. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2800-2806.	2.4	53
626	Multislice Spiral Computed Tomography for the Evaluation of Stent Patency After Left Main Coronary Artery Stenting. <i>Circulation</i> , 2006, 114, 645-653.	1.6	155
627	From Chaotic to Coordinated Clinical Research: The Case of Acetylcysteine. <i>Archives of Internal Medicine</i> , 2006, 166, 1668.	3.8	0
628	Use of Impella Recover(R) LP 2.5 left ventricular assist device during high-risk percutaneous coronary interventions; clinical, haemodynamic and biochemical findings. <i>EuroIntervention</i> , 2006, 2, 91-100.	3.2	24
629	Tirofiban and Sirolimus-Eluting Stent vs Abciximab and Bare-Metal Stent for Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 2109.	7.4	290
630	Comparison of early outcome of percutaneous coronary intervention for unprotected left main coronary artery disease in the drug-eluting stent era with versus without intravascular ultrasonic guidance. <i>American Journal of Cardiology</i> , 2005, 95, 644-647.	1.6	95

#	ARTICLE	IF	CITATIONS
631	Comparison of Short- (One Month) and Long- (Twelve Months) Term Outcomes of Sirolimus- Versus Paclitaxel-Eluting Stents in 293 Consecutive Patients With Diabetes Mellitus (from the RESEARCH and) Tj ETQq1 1 0.784314rgBT /Overlock	1.6	24
632	Immediate and One-Year Outcome of Percutaneous Intervention of Saphenous Vein Graft Disease With Paclitaxel-Eluting Stents. American Journal of Cardiology, 2005, 96, 395-398.	1.6	24
633	Left ventricular unloading and concomitant total cardiac output increase by the use of percutaneous impella recover LP 2.5 assist device during high-risk coronary intervention. Catheterization and Cardiovascular Interventions, 2005, 65, 263-267.	1.7	100
634	Rationale and methods of the integrated biomarker and imaging study (IBIS): combining invasive and non-invasive imaging with biomarkers to detect subclinical atherosclerosis and assess coronary lesion biology. International Journal of Cardiovascular Imaging, 2005, 21, 425-441.	1.5	36
635	One year clinical follow up of paclitaxel eluting stents for acute myocardial infarction compared with sirolimus eluting stents. Heart, 2005, 91, 1176-1180.	2.9	37
636	Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. European Heart Journal, 2005, 26, 1838-1845.	2.2	214
637	Intracardiac echocardiography guidance during percutaneous transluminal septal myocardial ablation in patients with obstructive hypertrophic cardiomyopathy. International Journal of Cardiovascular Interventions, 2005, 7, 134-137.	0.5	21
638	Tumor Necrosis Factor- α Receptor 1 Is a Major Predictor of Mortality and New-Onset Heart Failure in Patients With Acute Myocardial Infarction. Circulation, 2005, 111, 863-870.	1.6	185
639	Letters Regarding Article by Patti et al, "Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during) Tj ETQq1 1 0.784314rgBT /Overlock	1.6	24
640	Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease. Circulation, 2005, 111, 1383-1389.	1.6	305
641	Coronary artery remodelling is related to plaque composition. Heart, 2005, 92, 388-391.	2.9	114
642	New and old strategies to afford the liberal use of drug-eluting stents in real-life scenarios. Country Review Ukraine, 2005, 7, K31-K35.	0.8	1
643	Complete myocardial revascularization: between myth and reality. European Heart Journal, 2005, 26, 1809-1810.	2.2	1
644	Percutaneous therapy of bifurcation lesions with drug-eluting stent implantation: the Culotte technique revisited. International Journal of Cardiovascular Interventions, 2005, 7, 36-40.	0.5	32
645	Paclitaxel eluting stents for the treatment of angiographically non-significant atherosclerotic lesions. International Journal of Cardiovascular Interventions, 2005, 7, 68-71.	0.5	4
646	"Full metal jacket" (stented length \approx 64 mm) using drug-eluting stents for de novo coronary artery lesions. American Heart Journal, 2005, 150, 994-999.	2.7	74
647	The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population. Journal of the American College of Cardiology, 2005, 45, 1135-1141.	2.8	204
648	In Vivo Intravascular Ultrasound-Derived Thin-Cap Fibroatheroma Detection Using Ultrasound Radiofrequency Data Analysis. Journal of the American College of Cardiology, 2005, 46, 2038-2042.	2.8	364

#	ARTICLE	IF	CITATIONS
649	Title is missing!. European Heart Journal Supplements, 2004, 6, F22-F29.	0.1	11
650	CD34+and Endothelial Progenitor Cells in Patients With Various Degrees of Congestive Heart Failure. Circulation, 2004, 110, 1209-1212.	1.6	360
651	High-Dose Bolus Tirofiban and Sirolimus Eluting Stent versus Abiciximab and Bare Metal Stent in Acute Myocardial Infarction (STRATEGY) Study: Protocol Design and Demography of the First 100 Patients. Cardiovascular Drugs and Therapy, 2004, 18, 225-230.	2.6	15
652	Hydroxyl radical generation, levels of tumor necrosis factor-alpha, and progression to heart failure after acute myocardial infarction. Journal of the American College of Cardiology, 2004, 43, 2000-2008.	2.8	46
653	The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty. Journal of the American College of Cardiology, 2004, 44, 14-19.	2.8	151
654	Endothelial dysfunction in acute and chronic coronary syndromes: evidence for a pathogenetic role of oxidative stress. Archives of Biochemistry and Biophysics, 2003, 420, 255-261.	3.0	76
655	Serum From Patients With Acute Coronary Syndromes Displays a Proapoptotic Effect on Human Endothelial Cells. Circulation, 2003, 107, 264-270.	1.6	66
656	Myocardial ischaemia: new evidence for angiotensin-converting enzyme inhibition. European Heart Journal Supplements, 2003, 5, E11-E17.	0.1	6
657	Oxidative Stress EPR Measurement in Human Liver by Radical-probe Technique. Correlation with Etiology, Histology and Cell Proliferation. Free Radical Research, 2002, 36, 939-948.	3.3	97
658	Neurohormones, cytokines and programmed cell death in heart failure: a new paradigm for the remodeling heart. Cardiovascular Drugs and Therapy, 2001, 15, 529-537.	2.6	5
659	Serum Xanthine Oxidase in Human Liver Disease. American Journal of Gastroenterology, 2001, 96, 1194-1199.	0.4	49
660	Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices. Hepatology, 2000, 31, 349-357.	7.3	37
661	Left ventricular volumes in liver cirrhosis. Digestive and Liver Disease, 2000, 32, 392-397.	0.9	13
662	Measurement of oxidative stress in human liver by EPR spin-probe technique. Free Radical Research, 2000, 33, 167-178.	3.3	56
663	Splanchnic arterial doppler parameters in portal hypertension. Hepatology, 1999, 29, 1610-1610.	7.3	1
664	Systemic and splanchnic hemodynamic changes after liver transplantation for cirrhosis: A long-term prospective study. Hepatology, 1999, 30, 58-64.	7.3	141
665	Duplex Doppler findings in splenic arteriovenous fistula. , 1998, 26, 103-105.		10
666	A case of extracranial vertebral artery dissection with spontaneous recovery. European Journal of Ultrasound: Official Journal of the European Federation of Societies for Ultrasound in Medicine and Biology, 1997, 6, 197-201.	1.3	2

#	ARTICLE	IF	CITATIONS
667	Association of Serum PCSK9 with Near-Infrared Spectroscopy Derived Lipid Core Burden Index and Long-Term Cardiac Outcome. SSRN Electronic Journal, 0, , .	0.4	0